Cargando…

Advanced hormone receptor-positive/human epidermal growth factor receptor 2-positive invasive ductal carcinoma with cecal metastasis: A case report

The incidence of gastrointestinal metastases from breast cancer (BC) is low. We report a special case of Luminal B (Hormone Receptor positive [HR+]/Human Epidermal Growth Factor receptor 2-positive [HER-2+]) BC. The patient presented with asymptomatic brain metastases two years after radical surgery...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Si-Yuan, Zhang, Ji, Yang, Zhuang-Qing, Duan, Jia-Jun, Zhang, Ying, Li, Ming-Ke, Wang, Lei, Ye, Chun-mei, Nie, Jian-Yun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Medicine & Health Sciences
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576924/ https://www.ncbi.nlm.nih.gov/pubmed/37828835 http://dx.doi.org/10.1177/00368504231201043

Ejemplares similares

Neoadjuvant Chemotherapy or Endocrine Therapy for Invasive Ductal Carcinoma of the Breast With High Hormone Receptor Positivity and Human Epidermal Growth Factor Receptor 2 Negativity
por: Zhang, Jiaqiang, et al.
Publicado: (2021)

Investigating the effectiveness of adjuvant therapy for patients with hormone receptor-positive ductal carcinoma in situ
por: Tsai, Chi-Jui, et al.
Publicado: (2022)

Treatment strategies for hormone receptor-positive, human epidermal growth factor receptor 2-positive (HR+/HER2+) metastatic breast cancer: A review
por: Ran, Ran, et al.
Publicado: (2022)

Biological response to hormonal manipulation in oestrogen receptor positive ductal carcinoma in situ of the breast
por: Boland, G P, et al.
Publicado: (2003)

HPK1 positive expression associated with longer overall survival in patients with estrogen receptor-positive invasive ductal carcinoma-not otherwise specified
por: Wang, Jiaojiao, et al.
Publicado: (2017)

Survival Outcomes in Invasive Lobular Carcinoma Compared to Oestrogen Receptor-Positive Invasive Ductal Carcinoma
por: Timbres, Jasmine, et al.
Publicado: (2021)

Prolonged Time from Diagnosis to Breast-Conserving Surgery is Associated with Upstaging in Hormone Receptor-Positive Invasive Ductal Breast Carcinoma
por: Hills, Natalie, et al.
Publicado: (2021)

Recent advances in the treatment of hormone receptor-positive/human epidermal growth factor 2-positive advanced breast cancer
por: Lv, Huimin, et al.
Publicado: (2021)

Growth hormone receptor inhibition decreases the growth and metastasis of pancreatic ductal adenocarcinoma
por: Subramani, Ramadevi, et al.
Publicado: (2014)

Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors
por: Truin, Wilfred, et al.
Publicado: (2017)

Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas
por: Delpech, Y, et al.
Publicado: (2013)

Association of Adjuvant Hormone Therapy Timing With Overall Survival Among Patients With Hormone Receptor–Positive Human Epidermal Growth Factor Receptor-2–Negative Early Breast Cancer Without Chemotherapy
por: Fu, Fangmeng, et al.
Publicado: (2022)

Delaying Chemotherapy in the Treatment of Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
por: Brufsky, Adam M.
Publicado: (2015)

The role of sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer
por: Avila, Jorge, et al.
Publicado: (2023)

Predicting the Response of Neoadjuvant Chemotherapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer With Axillary Lymph Node Metastasis by Multigene Assay
por: Lee, Jun-Hee, et al.
Publicado: (2022)

Efficacy and safety of endocrine therapy after mastectomy in patients with hormone receptor positive breast ductal carcinoma in situ: Retrospective cohort study
por: Niu, Nan, et al.
Publicado: (2023)

Elevated tumor mutation burden and immunogenic activity in patients with hormone receptor-negative or human epidermal growth factor receptor 2-positive breast cancer
por: Xu, Junnan, et al.
Publicado: (2019)

The role of ultrasonographic findings for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer
por: Li, Shuo, et al.
Publicado: (2023)

Efficacy and safety of low-dose everolimus combined with endocrine drugs for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer
por: Zhang, Hui-Qiang, et al.
Publicado: (2021)

Fulvestrant in the treatment of hormone receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer: A review
por: Li, Junjie, et al.
Publicado: (2019)

Advances in endocrine and targeted therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
por: Shen, Le-Sang, et al.
Publicado: (2020)

Cost-effectiveness of sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer
por: Shi, Demin, et al.
Publicado: (2023)

Ki67/SATB1 ratio is an independent prognostic factor of overall survival in patients with early hormone receptor-positive invasive ductal breast carcinoma
por: Laurinavicius, Arvydas, et al.
Publicado: (2015)

Pyrotinib in combination with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer (PLEHERM): a multicenter, single-arm, phase II trial
por: Hu, Zhe-Yu, et al.
Publicado: (2023)

Therapeutic Strategies for the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Positive (HR+/HER2+) Breast Cancer: A Review of the Current Literature
por: Thanopoulou, Eirini, et al.
Publicado: (2020)

Brain metastasis in human epidermal growth factor receptor 2-positive breast cancer: from biology to treatment
por: Koo, Taeryool, et al.
Publicado: (2016)

The Immunology of Hormone Receptor Positive Breast Cancer
por: Goldberg, Jonathan, et al.
Publicado: (2021)

Patients’ preferences for postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treatments in Japan
por: Omori, Yukie, et al.
Publicado: (2019)

Histologic tumor type as a determinant of survival in hormone receptor-positive, HER2-negative, pT1-3 invasive ductal and lobular breast cancer
por: Göker, Menekse, et al.
Publicado: (2023)

The Significance of p-AKT1 as a Prognostic Marker and Therapeutic Target in Patients With Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor-2-Positive Early Breast Cancer
por: Kim, Ji Yea, et al.
Publicado: (2022)

Patterns of resource utilization and cost for postmenopausal women with hormone-receptor–positive, human epidermal growth factor receptor-2–negative advanced breast cancer in Europe
por: Jerusalem, Guy, et al.
Publicado: (2015)

Human Epidermal Growth Factor Receptor 2-Subtype Invasive Ductal Carcinoma Recurring as Basal-Human Epidermal Growth Factor Receptor 2-Subtype Squamous Cell Carcinoma
por: An, Jeongshin, et al.
Publicado: (2019)

Hormonal-receptor positive breast cancer: IL-6 augments invasion and lymph node metastasis via stimulating cathepsin B expression()
por: Ibrahim, Sherif A., et al.
Publicado: (2016)

Adenocarcinoma of the lung with positive epidermal growth factor receptor mutation in pregnancy
por: Amanda, Gina, et al.
Publicado: (2017)

Prognoses of Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy before Surgery: A Retrospective Analysis
por: Zhang, Shichao, et al.
Publicado: (2023)

Association Between Time to Operation and Pathologic Stage in Ductal Carcinoma in Situ and Early-Stage Hormone Receptor-Positive Breast Cancer
por: Minami, Christina A., et al.
Publicado: (2020)

BPIFB1 promotes metastasis of hormone receptor‐positive breast cancer via inducing macrophage M2‐like polarization
por: Hu, Anbang, et al.
Publicado: (2023)

Efficacy and Safety of Fulvestrant 500mg in Hormone-receptor Positive Human Epidermal Receptor 2 Negative Advanced Breast Cancer: A Real-world Study in China
por: Lei, Wen, et al.
Publicado: (2020)

Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers
por: Migliaccio, Ilenia, et al.
Publicado: (2015)

Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review
por: Nagaraj, Gayathri, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2ua97ufpbckkn2ma5g8vt1uabu